Misplaced Pages

LY-487,379: Difference between revisions

Article snapshot taken from[REDACTED] with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Browse history interactively← Previous editContent deleted Content addedVisualWikitext
Revision as of 23:37, 19 April 2011 editCheMoBot (talk | contribs)Bots141,565 edits Updating {{drugbox}} (no changed fields - added verified revid - updated 'UNII_Ref', 'ChemSpiderID_Ref', 'StdInChI_Ref', 'StdInChIKey_Ref', 'ChEMBL_Ref', 'KEGG_Ref') per Chem/Drugbox validation (← Previous edit Latest revision as of 19:32, 20 December 2023 edit undoJJMC89 bot III (talk | contribs)Bots, Administrators3,754,278 editsm Moving Category:Eli Lilly and Company brands to Category:Drugs developed by Eli Lilly and Company per Misplaced Pages:Categories for discussion/Log/2023 December 9#Category:AstraZeneca brands 
(32 intermediate revisions by 24 users not shown)
Line 1: Line 1:
{{Short description|Chemical compound}}
{{drugbox
{{Drugbox
| verifiedrevid = 413962947
| Verifiedfields = changed
| IUPAC_name = N-(4-(2-methoxyphenoxy)phenyl)- N-(2,2,2-trifluoroethylsulfonyl)pyrid- 3-ylmethylamine
| Watchedfields = changed
| image = LY-487,379_structure.png
| verifiedrevid = 424939072
| width = 200
| IUPAC_name = N-(4-(2-methoxyphenoxy)phenyl)- N-(2,2,2-trifluoroethylsulfonyl)pyrid- 3-ylmethylamine
| CAS_number =
| image = LY-487,3793Dan.svg
| ATC_prefix = none
| width = 200
| ATC_suffix =

| PubChem = 9825084
<!--Clinical data-->
| tradename =
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B / C / D / X -->
| pregnancy_category =
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_CA = <!-- / Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL / P / POM / CD / Class A, B, C -->
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
| legal_status =
| routes_of_administration =

<!--Pharmacokinetic data-->
| bioavailability =
| protein_bound =
| metabolism =
| elimination_half-life =
| excretion =

<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|CAS}}
| CAS_number = 353231-17-1
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 7WF5ZLL4D9
| ATC_prefix = none
| ATC_suffix =
| PubChem = 9825084
| IUPHAR_ligand = 1402 | IUPHAR_ligand = 1402
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| DrugBank =
| ChEMBL = 108939
| C=21|H=19|F=3|N=2|O=4|S=1
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| molecular_weight = 452.446 g/mol
| DrugBank =
| smiles = c3ncccc3CN(S(=O)(=O)CC(F)(F)F)c2ccc(cc2)Oc1ccccc1OC
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| bioavailability =
| protein_bound = | ChemSpiderID = 8000831

| metabolism =
<!--Chemical data-->
| elimination_half-life =
| excretion = | C=21 | H=19 | F=3 | N=2 | O=4 | S=1
| smiles = c3ncccc3CN(S(=O)(=O)CC(F)(F)F)c2ccc(cc2)Oc1ccccc1OC
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| StdInChI_Ref = {{stdinchicite|changed|chemspider}}
| pregnancy_US = <!-- A / B / C / D / X -->
| StdInChI = 1S/C21H19F3N2O4S/c1-29-19-6-2-3-7-20(19)30-18-10-8-17(9-11-18)26(14-16-5-4-12-25-13-16)31(27,28)15-21(22,23)24/h2-13H,14-15H2,1H3
| pregnancy_category=
| StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| StdInChIKey = ALMACYDZFBMGOR-UHFFFAOYSA-N
| legal_CA = <!-- / Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL / P / POM / CD / Class A, B, C -->
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
| legal_status =
| routes_of_administration =
}} }}


'''LY-487,379''' is a drug used in scientific research that acts as a selective ] for the ] group II subtype ].<ref>{{cite journal | vauthors = Johnson MP, Baez M, Jagdmann GE, Britton TC, Large TH, Callagaro DO, Tizzano JP, Monn JA, Schoepp DD | display-authors = 6 | title = Discovery of allosteric potentiators for the metabotropic glutamate 2 receptor: synthesis and subtype selectivity of N-(4-(2-methoxyphenoxy)phenyl)-N-(2,2,2- trifluoroethylsulfonyl)pyrid-3-ylmethylamine | journal = Journal of Medicinal Chemistry | volume = 46 | issue = 15 | pages = 3189–92 | date = July 2003 | pmid = 12852748 | doi = 10.1021/jm034015u }}</ref> It is used to study the structure and function of this receptor subtype,<ref>{{cite journal | vauthors = Schaffhauser H, Rowe BA, Morales S, Chavez-Noriega LE, Yin R, Jachec C, Rao SP, Bain G, Pinkerton AB, Vernier JM, Bristow LJ, Varney MA, Daggett LP | display-authors = 6 | title = Pharmacological characterization and identification of amino acids involved in the positive modulation of metabotropic glutamate receptor subtype 2 | journal = Molecular Pharmacology | volume = 64 | issue = 4 | pages = 798–810 | date = October 2003 | pmid = 14500736 | doi = 10.1124/mol.64.4.798 | s2cid = 15919973 }}</ref><ref>{{cite journal | vauthors = Poisik O, Raju DV, Verreault M, Rodriguez A, Abeniyi OA, Conn PJ, Smith Y | title = Metabotropic glutamate receptor 2 modulates excitatory synaptic transmission in the rat globus pallidus | journal = Neuropharmacology | volume = 49 | pages = 57–69 | year = 2005 | issue = Suppl 1 | pmid = 15993439 | doi = 10.1016/j.neuropharm.2005.03.006 | s2cid = 21881395 }}</ref> and LY-487,379 along with various other mGluR<sub>2/3</sub> agonists and positive modulators are being investigated as possible ] and ] drugs.<ref>{{cite journal | vauthors = Galici R, Echemendia NG, Rodriguez AL, Conn PJ | title = A selective allosteric potentiator of metabotropic glutamate (mGlu) 2 receptors has effects similar to an orthosteric mGlu2/3 receptor agonist in mouse models predictive of antipsychotic activity | journal = The Journal of Pharmacology and Experimental Therapeutics | volume = 315 | issue = 3 | pages = 1181–1187 | date = December 2005 | pmid = 16123306 | doi = 10.1124/jpet.105.091074 | s2cid = 9159875 | url = http://pdfs.semanticscholar.org/3000/65580e1d888e0d2383e21447ec7b1f1b6a6a.pdf | archive-url = https://web.archive.org/web/20190221225118/http://pdfs.semanticscholar.org/3000/65580e1d888e0d2383e21447ec7b1f1b6a6a.pdf | url-status = dead | archive-date = 2019-02-21 }}</ref><ref>{{cite journal | vauthors = Marino MJ, Conn PJ | title = Glutamate-based therapeutic approaches: allosteric modulators of metabotropic glutamate receptors | journal = Current Opinion in Pharmacology | volume = 6 | issue = 1 | pages = 98–102 | date = February 2006 | pmid = 16368268 | doi = 10.1016/j.coph.2005.09.006 }}</ref><ref>{{cite journal | vauthors = Harich S, Gross G, Bespalov A | title = Stimulation of the metabotropic glutamate 2/3 receptor attenuates social novelty discrimination deficits induced by neonatal phencyclidine treatment | journal = Psychopharmacology | volume = 192 | issue = 4 | pages = 511–9 | date = July 2007 | pmid = 17318501 | doi = 10.1007/s00213-007-0742-y | s2cid = 7551116 }}</ref><ref>{{cite journal | vauthors = Conn PJ, Jones CK | title = Promise of mGluR2/3 activators in psychiatry | journal = Neuropsychopharmacology | volume = 34 | issue = 1 | pages = 248–9 | date = January 2009 | pmid = 19079073 | pmc = 2907744 | doi = 10.1038/npp.2008.156 }}</ref><ref>{{cite journal | vauthors = Hermes ML, Renaud LP | title = Postsynaptic and presynaptic group II metabotropic glutamate receptor activation reduces neuronal excitability in rat midline paraventricular thalamic nucleus | journal = The Journal of Pharmacology and Experimental Therapeutics | volume = 336 | issue = 3 | pages = 840–9 | date = March 2011 | pmid = 21139059 | doi = 10.1124/jpet.110.176149 | s2cid = 25111011 | url = http://pdfs.semanticscholar.org/3338/3c0769e7c9f9bffbedd6fdbfec4124dc0140.pdf | archive-url = https://web.archive.org/web/20190222071207/http://pdfs.semanticscholar.org/3338/3c0769e7c9f9bffbedd6fdbfec4124dc0140.pdf | url-status = dead | archive-date = 2019-02-22 }}</ref>
'''LY-487,379''' is a drug used in scientific research that acts as a selective ] for the ] group II subtype ].<ref>{{Cite pmid|12852748}}</ref> It is used to study the structure and function of this receptor subtype,<ref>{{Cite journal | first1 = H.
| author2 = Rowe
| author3 = Morales
| last1 = Schaffhauser | first2 = B. A. | first3 = S.
| last4 = Chavez-noriega
| last6 = Jachec
| author4 = Chavez-noriega | first4 = L. E.
| author5 = Yin | first5 = R.
| last7 = Rao
| last5 = Yin
| last3 = Morales
| author6 = Jachec
| last2 = Rowe
| author1 = | first6 = C.
| author7 = Rao
| last9 = Pinkerton | first7 = S. P.
| author8 = Bain | first8 = G.
| author9 =Pinkerton | first9 = A. B.
| title = Pharmacological Characterization and Identification of Amino Acids Involved in the Positive Modulation of Metabotropic Glutamate Receptor Subtype 2
| journal = Molecular Pharmacology
| volume = 64 | issue = 4
| pages = 798–810
| last8 = Bain
| year = 2003 | pmid = 14500736 | first10 = JM
| doi = 10.1124/mol.64.4.798
}}</ref><ref>{{Cite journal
| author1 = | first1 = O.
| author2 =
| last1 = Poisik
| last2 = Raju | first2 = D. V.
| author3 =
| last3 = Verreault| first3 = M.
| author4 =
| last4 = Rodriguez| first4 = A.
| author5 =
| last5 = Abeniyi| first5 = O. A.
| author6 =
| last6 = Conn| first6 = P. J.
| author7 =
| last7 = Smith| first7 = Y.
| title = Metabotropic glutamate receptor 2 modulates excitatory synaptic transmission in the rat globus pallidus
| journal = Neuropharmacology
| volume = 49
| pages = 57–50
| year = 2005
| doi = 10.1016/j.neuropharm.2005.03.006| pmid=15993439
}}</ref> and LY-487,379 along with various other mGluR<sub>2/3</sub> agonists and positive modulators are being investigated as possible ] and ] drugs.<ref>{{Cite journal
| author1 = | first1 = R. | first2 = N. G.
| author3 =
| last1 = Galici
| author2 = | first3 = A. L. | first4 = P. J.
| title = A Selective Allosteric Potentiator of Metabotropic Glutamate (mGlu) 2 Receptors Has Effects Similar to an Orthosteric mGlu2/3 Receptor Agonist in Mouse Models Predictive of Antipsychotic Activity
| journal = Journal of Pharmacology and Experimental Therapeutics
| last3 = Rodriguez
| volume = 315
| last4 = Conn
| issue = 3
| pages = 1181–7
| year = 2005
| pmid = 16123306
| doi = 10.1124/jpet.105.091074
| last2 = Echemendia
| author4 =
}}</ref><ref>{{Cite pmid|16368268}}</ref><ref>{{Cite pmid|17318501}}</ref><ref>{{Cite pmid|190790739}}</ref>


==See also== == See also ==
* ] * ]
* ] * ]


== References == == References ==
{{reflist}} {{Reflist|2}}

{{Glutamate_receptor_ligands}}


{{Metabotropic glutamate receptor modulators}}
]


]
]
]


{{pharmacology-stub}} {{nervous-system-drug-stub}}

Latest revision as of 19:32, 20 December 2023

Chemical compound Pharmaceutical compound
LY-487,379
Clinical data
ATC code
  • none
Identifiers
IUPAC name
  • N-(4-(2-methoxyphenoxy)phenyl)- N-(2,2,2-trifluoroethylsulfonyl)pyrid- 3-ylmethylamine
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC21H19F3N2O4S
Molar mass452.45 g·mol
3D model (JSmol)
SMILES
  • c3ncccc3CN(S(=O)(=O)CC(F)(F)F)c2ccc(cc2)Oc1ccccc1OC
InChI
  • InChI=1S/C21H19F3N2O4S/c1-29-19-6-2-3-7-20(19)30-18-10-8-17(9-11-18)26(14-16-5-4-12-25-13-16)31(27,28)15-21(22,23)24/h2-13H,14-15H2,1H3
  • Key:ALMACYDZFBMGOR-UHFFFAOYSA-N
  (what is this?)  (verify)

LY-487,379 is a drug used in scientific research that acts as a selective positive allosteric modulator for the metabotropic glutamate receptor group II subtype mGluR2. It is used to study the structure and function of this receptor subtype, and LY-487,379 along with various other mGluR2/3 agonists and positive modulators are being investigated as possible antipsychotic and anxiolytic drugs.

See also

References

  1. Johnson MP, Baez M, Jagdmann GE, Britton TC, Large TH, Callagaro DO, et al. (July 2003). "Discovery of allosteric potentiators for the metabotropic glutamate 2 receptor: synthesis and subtype selectivity of N-(4-(2-methoxyphenoxy)phenyl)-N-(2,2,2- trifluoroethylsulfonyl)pyrid-3-ylmethylamine". Journal of Medicinal Chemistry. 46 (15): 3189–92. doi:10.1021/jm034015u. PMID 12852748.
  2. Schaffhauser H, Rowe BA, Morales S, Chavez-Noriega LE, Yin R, Jachec C, et al. (October 2003). "Pharmacological characterization and identification of amino acids involved in the positive modulation of metabotropic glutamate receptor subtype 2". Molecular Pharmacology. 64 (4): 798–810. doi:10.1124/mol.64.4.798. PMID 14500736. S2CID 15919973.
  3. Poisik O, Raju DV, Verreault M, Rodriguez A, Abeniyi OA, Conn PJ, Smith Y (2005). "Metabotropic glutamate receptor 2 modulates excitatory synaptic transmission in the rat globus pallidus". Neuropharmacology. 49 (Suppl 1): 57–69. doi:10.1016/j.neuropharm.2005.03.006. PMID 15993439. S2CID 21881395.
  4. Galici R, Echemendia NG, Rodriguez AL, Conn PJ (December 2005). "A selective allosteric potentiator of metabotropic glutamate (mGlu) 2 receptors has effects similar to an orthosteric mGlu2/3 receptor agonist in mouse models predictive of antipsychotic activity" (PDF). The Journal of Pharmacology and Experimental Therapeutics. 315 (3): 1181–1187. doi:10.1124/jpet.105.091074. PMID 16123306. S2CID 9159875. Archived from the original (PDF) on 2019-02-21.
  5. Marino MJ, Conn PJ (February 2006). "Glutamate-based therapeutic approaches: allosteric modulators of metabotropic glutamate receptors". Current Opinion in Pharmacology. 6 (1): 98–102. doi:10.1016/j.coph.2005.09.006. PMID 16368268.
  6. Harich S, Gross G, Bespalov A (July 2007). "Stimulation of the metabotropic glutamate 2/3 receptor attenuates social novelty discrimination deficits induced by neonatal phencyclidine treatment". Psychopharmacology. 192 (4): 511–9. doi:10.1007/s00213-007-0742-y. PMID 17318501. S2CID 7551116.
  7. Conn PJ, Jones CK (January 2009). "Promise of mGluR2/3 activators in psychiatry". Neuropsychopharmacology. 34 (1): 248–9. doi:10.1038/npp.2008.156. PMC 2907744. PMID 19079073.
  8. Hermes ML, Renaud LP (March 2011). "Postsynaptic and presynaptic group II metabotropic glutamate receptor activation reduces neuronal excitability in rat midline paraventricular thalamic nucleus" (PDF). The Journal of Pharmacology and Experimental Therapeutics. 336 (3): 840–9. doi:10.1124/jpet.110.176149. PMID 21139059. S2CID 25111011. Archived from the original (PDF) on 2019-02-22.
Metabotropic glutamate receptor modulators
Group I
mGluR1Tooltip Metabotropic glutamate receptor 1
mGluR5Tooltip Metabotropic glutamate receptor 5
Group II
mGluR2Tooltip Metabotropic glutamate receptor 2
mGluR3Tooltip Metabotropic glutamate receptor 3
Group III
mGluR4Tooltip Metabotropic glutamate receptor 4
mGluR6Tooltip Metabotropic glutamate receptor 6
mGluR7Tooltip Metabotropic glutamate receptor 7
mGluR8Tooltip Metabotropic glutamate receptor 8
See also: Receptor/signaling modulators • Ionotropic glutamate receptor modulators • Glutamate metabolism/transport modulators
Stub icon

This drug article relating to the nervous system is a stub. You can help Misplaced Pages by expanding it.

Categories:
LY-487,379: Difference between revisions Add topic